ReviewFrontiers in endocrinology2026
Regulatory networks of post-translational modifications in diabetic kidney disease: from pathogenic mechanisms to therapeutic frontiers.
Review in Frontiers in endocrinology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Diabetic kidney disease (DKD) remains a principal microvascular complication of diabetes, driven by a multifaceted pathogenesis that extends beyond pure metabolic dysregulation. Post-translational modifications (PTMs) have emerged as pivotal mechanisms that dynamically regulate protein function and stability under diabetic stress. This review provides a comprehensive synthesis of the regulatory networks governing PTMs in DKD, systematically dissecting the molecular landscapes of phosphorylation, acetylation, ubiquitination, glycosylation, methylation, and SUMOylation. Beyond clarifying individual pathogenic mechanisms, the dysregulation of PTM networks links systemic metabolic disturbances to persistent renal injury. Furthermore, we evaluate emerging therapeutic strategies designed to modulate these modifications. We conclude that targeting PTMs represents a critical advance in DKD therapy, shifting from broad symptomatic management to precise molecular intervention-offering new directions for arresting the progression of DKD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.